Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Krystal Biotech, Inc.KRYS · Entity 3500 | Director · President, R&D · 10% owner | September 04, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Krystal Biotech, Inc.
Report date September 04, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,302,145 |
Ending reported balance
After 2026-09-04 transaction · row 13
13 source rows · reconciled sequenceRow 1 · 2026-09-04 · Sale · Disposed 520 · Balance 1,326,625 F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 2 · 2026-09-04 · Sale · Disposed 2,006 · Balance 1,324,619 F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 3 · 2026-09-04 · Sale · Disposed 3,267 · Balance 1,321,352 F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 4 · 2026-09-04 · Sale · Disposed 3,962 · Balance 1,317,390 F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 5 · 2026-09-04 · Sale · Disposed 3,180 · Balance 1,314,210 F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2026-09-04 · Sale · Disposed 3,392 · Balance 1,310,818 F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2026-09-04 · Sale · Disposed 2,320 · Balance 1,308,498 F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2026-09-04 · Sale · Disposed 1,242 · Balance 1,307,256 F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 9 · 2026-09-04 · Sale · Disposed 1,992 · Balance 1,305,264 F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 10 · 2026-09-04 · Sale · Disposed 565 · Balance 1,304,699 F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 11 · 2026-09-04 · Sale · Disposed 1,329 · Balance 1,303,370 F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 12 · 2026-09-04 · Sale · Disposed 826 · Balance 1,302,544 F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 13 · 2026-09-04 · Sale · Disposed 399 · Balance 1,302,145 F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Spousal Trust | 90,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 90,000 F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Suma Mani Krishnan Trust | 51,010 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · Balance 51,010 F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Krishnan Family Trust | 50,000 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 50,000 F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
F2: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated.
F3: The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6: The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7: The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F8: The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F9: The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F10: The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F11: The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F12: The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F13: The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F14: The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F15: The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F16: Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee.
F17: Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust.
F18: Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 700 | $222.20 | $155,539.02 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 18 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,483,056 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F20 · price: The transaction was executed in multiple trades ranging from $222.14 to $222.30. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,505 | $221.78 | $2,329,771.59 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 17 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,483,756 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F19 · price: The transaction was executed in multiple trades ranging from $221.14 to $222.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,625 | $220.34 | $578,394.60 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 16 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,494,261 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F18 · price: The transaction was executed in multiple trades ranging from $220.14 to $221.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,693 | $219.53 | $1,249,803.08 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 15 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,496,886 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F17 · price: The transaction was executed in multiple trades ranging from $219.14 to $220.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,577 | $218.72 | $563,637.83 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 14 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,502,579 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F16 · price: The transaction was executed in multiple trades ranging from $218.11 to $219.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,600 | $217.04 | $347,271.68 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 13 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,505,156 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F15 · price: The transaction was executed in multiple trades ranging from $216.73 to $217.63. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 344 | $215.48 | $74,125.60 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 12 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,506,756 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F14 · price: The transaction was executed in multiple trades ranging from $214.99 to $215.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 956 | $214.28 | $204,851.39 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,507,100 F11 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F12 · price: The transaction was executed in multiple trades ranging from $213.93 to $214.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F13 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 200 | $222.38 | $44,475.00 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,413,711 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F9 · price: The transaction was executed in multiple trades ranging from $222.34 to $222.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,461 | $221.82 | $2,320,470.53 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,413,911 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F8 · price: The transaction was executed in multiple trades ranging from $221.21 to $222.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,627 | $220.52 | $579,300.52 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,424,372 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F7 · price: The transaction was executed in multiple trades ranging from $220.21 to $221.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 5,419 | $219.68 | $1,190,422.62 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,426,999 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F6 · price: The transaction was executed in multiple trades ranging from $219.21 to $220.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 3,593 | $218.83 | $786,244.69 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,432,418 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F5 · price: The transaction was executed in multiple trades ranging from $218.21 to $219.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,400 | $216.97 | $303,753.52 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,436,011 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F4 · price: The transaction was executed in multiple trades ranging from $216.60 to $217.53. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 600 | $215.49 | $129,295.98 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,437,411 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F3 · price: The transaction was executed in multiple trades ranging from $215.34 to $215.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 23:56 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 700 | $214.25 | $149,975.21 |
DisclosureSEC source: 0001298711-25-000013 · wk-form4_1764978975.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,438,011 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. F2 · price: The transaction was executed in multiple trades ranging from $213.87 to $214.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 16, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,389 | $150.00 | $208,350.00 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,508,056 F6 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in one trade. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| July 16, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,529 | $150.00 | $229,350.00 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,438,711 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in one trade. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 900 | $151.79 | $136,611.00 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,509,445 F6 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in one trade. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,184 | $150.68 | $329,088.83 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,510,345 F6 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F9 · price: The transaction was executed in multiple trades ranging from $150.21 to $151.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 800 | $151.79 | $121,432.00 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,440,240 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in one trade. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 2,236 | $150.68 | $336,929.20 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,441,040 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F4 · price: The transaction was executed in multiple trades ranging from $150.21 to $151.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 13,400 | $150.30 | $2,014,014.64 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,512,529 F6 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F7 · price: The transaction was executed in multiple trades ranging from $150.00 to $150.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 100 | $151.00 | $15,100.00 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,276 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F3 · price: The transaction was executed in one trade. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 22:42 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 13,335 | $150.29 | $2,004,125.15 |
DisclosureSEC source: 0001298711-25-000009 · wk-form4_1752705765.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,443,376 F1 · shares: The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on September 12, 2024, and contemplated quarterly sales of 25,000 shares of Common Stock. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. F2 · price: The transaction was executed in multiple trades ranging from $150.00 to $150.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 21:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 300 | $151.39 | $45,416.01 |
DisclosureSEC source: 0001298711-25-000007 · wk-form4_1752270332.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,525,929 F6 · shares: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025. F4 · price: The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 21:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,627 | $150.22 | $995,497.34 |
DisclosureSEC source: 0001298711-25-000007 · wk-form4_1752270332.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,526,229 F6 · shares: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025. F3 · price: The transaction was executed in multiple trades ranging from $150.0000 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 21:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 300 | $151.39 | $45,416.01 |
DisclosureSEC source: 0001298711-25-000007 · wk-form4_1752270332.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,456,711 F1 · shares: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 . F4 · price: The transaction was executed in three trades of 100 shares each at $151.350, $151.40, and $151.41, respectively. The price reported above reflects the average sale price. Read SEC document |
| July 10, 2025 Filed Jul 11, 2025 21:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,500 | $150.23 | $976,463.80 |
DisclosureSEC source: 0001298711-25-000007 · wk-form4_1752270332.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,457,011 F1 · shares: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 . F3 · price: The transaction was executed in multiple trades ranging from $150.0000 to $150.8500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 200 | $150.07 | $30,014.00 |
DisclosureSEC source: 0001298711-25-000007 · wk-form4_1752270332.xml · nonDerivative · entry 6 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,532,856 F6 · shares: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, that started on September 12, 2024 and will terminate on September 13, 2025. F7 · price: The transaction was executed in two trades of 100 shares each at $150 and $150.14, respectively. The price reported above reflects the average sale price. F8 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 21:45 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 200 | $150.14 | $30,027.80 |
DisclosureSEC source: 0001298711-25-000007 · wk-form4_1752270332.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,463,511 F1 · shares: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person that started on September 12, 2024 and will terminate on September 13, 2025 . F2 · price: The transaction was executed in multiple trades ranging from $150.1200 to $150.1600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,256 | $179.57 | $225,544.32 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 12 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,533,056 F8 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F14 · price: The transaction was executed in multiple trades ranging from $179.29 to $179.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,769 | $178.77 | $1,210,076.53 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,534,312 F8 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F13 · price: The transaction was executed in multiple trades ranging from $178.29 to $179.27. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,931 | $177.62 | $1,941,611.22 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,541,081 F8 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F12 · price: The transaction was executed in multiple trades ranging from $177.28 to $178.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,944 | $176.80 | $874,122.93 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,552,012 F8 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F11 · price: The transaction was executed in multiple trades ranging from $176.28 to $177.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,100 | $175.83 | $193,408.16 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Indirect · By Spouse Disclosed balance after: 1,556,956 F8 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F9 · price: The transaction was executed in multiple trades ranging from $175.23 to $176.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,331 | $179.55 | $238,976.52 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 5 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,463,711 F1 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F6 · price: The transaction was executed in multiple trades ranging from $179.33 to $179.70. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 6,514 | $178.76 | $1,164,415.28 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 4 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,465,042 F1 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F5 · price: The transaction was executed in multiple trades ranging from $178.31 to $179.26. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 10,937 | $177.66 | $1,943,026.95 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 3 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,471,556 F1 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F4 · price: The transaction was executed in multiple trades ranging from $177.30 to $178.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 4,579 | $176.88 | $809,923.90 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 2 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,482,493 F1 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F3 · price: The transaction was executed in multiple trades ranging from $176.30 to $177.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 13, 2025 Filed Mar 13, 2025 22:06 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | SaleCommon Stock | 1,639 | $175.97 | $288,418.76 |
DisclosureSEC source: 0001298711-25-000004 · wk-form4_1741903582.xml · nonDerivative · entry 1 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,487,072 F1 · kind: The sales reported were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 13, 2024. The Rule 10b5-1 trading plan started on September 12, 2024 and will terminate on September 13, 2025 and contemplates quarterly sales of 25,000 shares of common stock with a limit price of $150.00 per share. F2 · price: The transaction was executed in multiple trades ranging from $175.30 to $176.28. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantRestricted Stock Units · Derivative | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · derivative · entry 18 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed F19 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. F20 · shares: The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. F21 · derivative.exercise_date: The RSUs vest in four equal annual installments with the first installment vesting on February 28, 2026. F21 · derivative.expiration_date: The RSUs vest in four equal annual installments with the first installment vesting on February 28, 2026. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $179.25 | $0.00 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · derivative · entry 17 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-02-28 F18 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 28, 2026. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · derivative · entry 16 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 22,500 PSUs, vested on February 28, 2025. F6 · derivative.exercise_date: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 22,500 PSUs, vested on February 28, 2025. F6 · derivative.expiration_date: 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 22,500 PSUs, vested on February 28, 2025. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionPerformance Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · derivative · entry 15 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: 15,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2024, and the remaining 7,500 PSUs vested on February 28, 2025. F3 · derivative.exercise_date: 15,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2024, and the remaining 7,500 PSUs vested on February 28, 2025. F3 · derivative.expiration_date: 15,000 performance stock units ("PSUs") were granted on February 28, 2023. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2023, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 7,500 PSUs, vested on February 28, 2024, and the remaining 7,500 PSUs vested on February 28, 2025. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 12,149 | $179.25 | $2,177,708.25 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · nonDerivative · entry 11 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,562,777 F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F15 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 26,250 PSUs on February 28, 2025. F5 · price: The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · nonDerivative · entry 10 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,574,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F14 · shares: 52,500 PSUs were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's spouse continued service to the Company on each applicable vesting date following such achievement. The PSUs vest ratably over a two-year period. All of the performance criteria were achieved and one-half of the PSUs granted, or 26,250 PSUs, vested on February 28, 2025. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 4,050 | $179.25 | $725,962.50 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · nonDerivative · entry 9 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,548,676 F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F13 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 8,750 RSUs on February 28, 2025. F5 · price: The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · nonDerivative · entry 8 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,552,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F12 · shares: 35,000 restricted stock units ("RSUs") were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each RSU represented a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 8,750 RSUs, vesting on February 28, 2025. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
| February 28, 2025 Filed Mar 1, 2025 00:00 UTC | Krystal Biotech, Inc. KRYS · Entity 3500 | Tax withholdingCommon Stock | 5,786 | $179.25 | $1,037,140.50 |
DisclosureSEC source: 0001298711-25-000002 · wk-form4_1740787199.xml · nonDerivative · entry 7 Krishnan Suma · CIK 0001298711 · Director · President, R&D · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,543,976 F9 · shares: These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan. F11 · shares: Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 12,500 PSUs on February 28, 2025. F5 · price: The closing price on February 28, 2025 of the Company's common stock on the Nasdaq Global Select Market. F10 · ownership.nature: Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.